MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Treatments

Home
Treatments

Neuroprotection by Novel T Cell Enzyme Inhibitor

MStranslate
December 9, 2015
Research, Treatments
Research Summary: Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo The background Previous studies have shown that immune cells, known as cytotoxic T cells, are critical in the...

Statement on HSCT for MS: Professor Eva Havrdova

MStranslate
December 7, 2015
Research, Stem Cells, Treatments
Professor Eva Havrdova from Charles University in Prague presented at the recent ECTRIMS Congress, where she discussed the use of Hematopoietic Stem Cell Transplantation (HSCT) for the treatment of multiple...
video

Determining the Effectiveness of MS Treatments

MStranslate
November 24, 2015
Social Media, Treatments, Uncategorized
A short video summarising the key findings of a recent paper, titled "Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple...
Stem Cell Therapy

Evaluating Stem Cell Therapy for Progressive MS

MStranslate
September 22, 2015
Research, Stem Cells, Treatments
A publication this week in BMJ Open has outlined a number of studies evaluating the use of stem cell therapy for people with progressive multiple sclerosis. These trials, being conducted by a team from...
Clinical Trial

MIS416: A Clinical Trial for Secondary Progressive MS

MStranslate
August 26, 2015
Clinical Trials, Research, Treatments
Due to the lack of available treatment options for people with secondary progressive multiple sclerosis (SPMS), the development of novel therapies is vitally important. We sat down with Simon Wilkinson (CEO,...
Stem Cell Therapy

Stem Cell Therapy in Multiple Sclerosis

MStranslate
June 18, 2015
Stem Cells, Treatments
A/Prof Helmut Butzkueven from the Melbourne Brain Centre speaks with us to help clear up the confusion surrounding the use of Stem Cell Therapy in multiple sclerosis. He explains how stem cells are currently...

Vitamin B7 – Potential New Therapy for Progressive MS

MStranslate
May 13, 2015
Research, Treatments
Progressive MS is (finally) starting to be a major focus of MS research - both in trying to understand what triggers the shift from the relapsing-remitting form and in the development of effective treatments...

Nanoparticles Used to Deliver Myelin Repair Molecule

MStranslate
May 7, 2015
Research, Treatments
In recent years, a large focus of MS research around the world has been promoting remyelination - that is, the process of repairing damaged nerves. In a recent study published in Biomaterials Science, a team...

Use of Steroids to Treat Spasticity in MS

MStranslate
September 29, 2014
Research, Treatments
By Brett Drummond Spasticity is a common symptom in people with multiple sclerosis, having a major impact on quality of life and imposing a financial burden. There are a number of current treatments for...

Fingolimod After Natalizumab & Short-term Relapse Risk

MStranslate
March 27, 2014
Fingolimod, Natalizumab, Research, Treatments
Dr Vilija Jokubaitis et al Natalizumab (Tysabri) is an antibody used for the treatment of multiple sclerosis (MS). It is currently the strongest drug available for the treatment of MS, however, it has also...
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8
  7. 9

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.